Skip to content

Article: Nicotinamide Riboside Supplementation Benefits in Early Parkinson's Disease: Clinical Findings

Nicotinamide Riboside Supplementation Benefits in Early Parkinson's Disease: Clinical Findings


Objectives

To assess the safety, tolerability, and cerebral penetration of NR therapy in Parkinson's disease (PD) patients, as well as determine if NR has an impact on their neurometabolic profile and motor symptoms.

Journal

Cell Metabolism

Key Outcomes

  • NR supplementation significantly increased cerebral NAD+ levels, altered brain metabolic pattern, and decreased levels of inflammatory cytokines in the cerebrospinal fluid of PD patients.
  • Moreover, patients experienced a mild but significant clinical improvement, and this correlated with the change in the brain's metabolic pattern.

Duration

30 days

Dose

1000 mg

Study Design

Randomized, double-blind, placebo-controlled, phase I study in 30 Parkinson's disease (PD) patients

Read more

Autoimmune Disease

Nicotinamide Riboside Supplementation Boosts NAD+ and Lowers Inflammatory Immune Signaling in Lupus: Clinical Findings

Objectives To explore the anti-inflammatory effects of NR in monocytes (a type of white blood cell; immune cell) extracted from young, healthy subjects following supplementation. Additionally, the...

Read more
Cardiovascular Disease

Nicotinamide Riboside Supplementation Is Safe and Well-Tolerated in Heart Failure Patients: Clinical Findings

Objectives To assess the safety and tolerability of NR in patients with Stage C heart failure with reduced ejection fraction (HFrEF). Journal JACC: Basic to Translational Science Key Outcomes Hig...

Read more